PUREVAX Feline Rabies

Manufacturer: Merial

Rabies Vaccine

Live Canarypox Vector

rRabies

SWD

DESCRIPTION

PUREVAX^® Feline Rabies contains a nonadjuvanted lyophilized suspension of a recombinant vectored rabies vaccine plus a sterile water diluent. A canarypox vector has been modified, using recombinant technology, to produce expression of desired antigens capable of stimulating a protective immune response to rabies. Safety and immunogenicity of this product have been demonstrated by vaccination and challenge tests in susceptible cats.

INDICATIONS

PUREVAX^® Feline Rabies is recommended for the vaccination of healthy cats 12 weeks of age and older for prevention of disease due to rabies virus.

DOSAGE

Reconstitute the lyophilized vaccine with accompanying liquid diluent and aseptically inject 1 mL (1 dose) subcutaneously into healthy cats. Revaccinate annually with a single 1 mL dose.

PRECAUTIONS

Store at 2-7°C (35-45°F). Use immediately after reconstitution. Do not use chemicals to sterilize syringes and needles. Burn this container and all unused contents. Contains gentamicin as a preservative. It is generally recommended to avoid vaccination of pregnant cats. In rare instances, administration of vaccines may cause lethargy, fever, and inflammatory or hypersensitivity types of reactions. Treatment may include antihistamines, anti-inflammatories, and/or epinephrine.

SOLD TO VETERINARIANS ONLY.

For Veterinary Use Only.

PUREVAX is a registered trademark of MERIAL.

Manufactured By MERIAL INC., Athens, GA 30601 USA

U.S. Vet. Lic. No. 298

1-888-Merial-1 (1-888-637-4251)

Distributed In Canada By MERIAL CANADA, INC., Baie d’Urfé, (Québec), H9X 3V1, Canada

Contains		Prod. No.
25 Doses	25 x 1 Dose, Lyophilized 25 x 1 mL, Sterile Water	2136-25	RM860R8

Nac No.

11110584